subscribeSubscribe
J&J seeks expanded approvals for paediatric HIV-1 therapy

J&J seeks expanded approvals for paediatric HIV-1 therapy
PHARMACEUTICAL TECHNOLOGY
05 Jun 2024
Share Share
FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets

FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets
FDA
15 Jun 2023
Share Share
Fore Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394

Fore Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394
BUSINESSWIRE
12 Sep 2022
Share Share
FDA Confirms Paragraph IV Patent Challenge of Symtuza 210455 (Darunavir, Cobicistat, Emtricitabine, Tenofovir Alefenamide) 80mg/ 150mg/ 200mg/ 10mg tablets

FDA Confirms Paragraph IV Patent Challenge of Symtuza 210455 (Darunavir, Cobicistat, Emtricitabine, Tenofovir Alefenamide) 80mg/ 150mg/ 200mg/ 10mg tablets
FDA
06 Oct 2021
Share Share
J&J-backed AIDS film picked up by Verizon Media

J&J-backed AIDS film picked up by Verizon Media
Beth Snyder Bulik FIERCE PHARMA
10 May 2019
Share Share
Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen
PR NEWSWIRE
11 Apr 2019
Share Share
Mylan Pharms Generic Atazanavir; Cobicistat Receives Tentative Approval in US

Mylan Pharms Generic Atazanavir; Cobicistat Receives Tentative Approval in US
FDA
28 Mar 2019
Share Share
Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma

Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma
PATENT LITIGATION
29 Jan 2019
Share Share
FDA Confirms Paragraph IV Patent Challenge of Stribild 203100 (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) Tablets

FDA Confirms Paragraph IV Patent Challenge of Stribild 203100 (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) Tablets
FDA
12 Dec 2018
Share Share
NHS England agrees to fund Janssen’s Symtuza

NHS England agrees to fund Janssen’s Symtuza
Selina McKee PHARMA TIMES
02 Oct 2018
Share Share